
Roche’s Kadcyla beats Herceptin breast cancer disease recurrence and death risk
pharmafile | October 16, 2018 | News story | Manufacturing and Production, Sales and Marketing | Cancer, Kadcyla, Roche, breast cancer, pharma
Roche has unveiled new data for its antibody-drug conjugate Kadcyla (trastuzumab emtansine) in the treatment of patients with HER2-positive early breast cancer (eBC) who have residual disease (pathological invasive residual disease in the breast and/or axillary nodes) present following pre-surgery treatment.
The results from the Phase 3 KATHERINE study indicated that Kadcyla met its primary endpoint, “significantly reducing” the risk of disease recurrence or death compared to Herceptin (trastuzumab) when used as an adjuvant therapy.
“We are highly encouraged by these positive results with adjuvant Kadcyla treatment in people with HER2-positive early breast cancer who have residual disease after neoadjuvant therapy,” remarked Dr Sandra Horning, Roche’s Chief Medical Officer and Head of Global Product Development. “We look forward to discussions with regulatory authorities with the goal of bringing this new treatment option to patients as soon as possible.”
Full results from the study are due to be presented at the 2018 San Antonio Breast Cancer Symposium in December, and will be presented to global health authorities in the pursuit of marketing authorisation.
Matt Fellows
Related Content

Charity commits £800,000 to AI research into late breast cancer recurrence
Breast Cancer Now is investing £800,000 in two research projects using artificial intelligence to investigate …

Most advanced breast cancer patients treated in community settings, Phesi study finds
Most patients with advanced hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer are treated in community settings …

Amphista doses first patient in AML trial of protein degrader
Amphista Therapeutics has dosed the first patient in a phase 1 trial of AMX-883, an …






